| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/29/2006 | WO2006068928A1 Pyrrolo[1,2-a]quinoxalin-5-(4h)-yl)sulfonyls and carbonyls and their use as estrogenic agents |
| 06/29/2006 | WO2006068904A1 Tetrahydroquinoline analogues as muscarinic agonists |
| 06/29/2006 | WO2006068890A2 Lipid particles comprising bioactive agents, methods of preparing and uses thereof |
| 06/29/2006 | WO2006068829A1 Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| 06/29/2006 | WO2006068796A2 Inhibitors of akt activity |
| 06/29/2006 | WO2006068779A2 Compositions and methods of their use for improving the condition and appearance of skin |
| 06/29/2006 | WO2006068770A1 Spiro-2, 4-pyrimidinediamine compounds and their uses |
| 06/29/2006 | WO2006068760A2 Anti-inflammatory pyrazolopyrimidines |
| 06/29/2006 | WO2006068729A2 Methods and compositions for enhancing iron absorption |
| 06/29/2006 | WO2006068715A2 Cosmetic compositions having carnitine creatinate and methods for using |
| 06/29/2006 | WO2006068713A2 3,3'-diindolylmethane immune activating compositions |
| 06/29/2006 | WO2006068697A2 Compositions including iron |
| 06/29/2006 | WO2006068665A1 Antimicrobial compositions comprising a natural agent selected from gallic acid, eucalyptol, naringin, a jasmonic acid compound and any combination thereof |
| 06/29/2006 | WO2006068618A1 New compounds |
| 06/29/2006 | WO2006068596A1 Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| 06/29/2006 | WO2006068594A1 HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY |
| 06/29/2006 | WO2006068593A1 New benzothiazolesulfonamides |
| 06/29/2006 | WO2006068592A1 New benzothiazolecarboxamides |
| 06/29/2006 | WO2006068591A1 Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors |
| 06/29/2006 | WO2006068516A1 Implantable medical devices coated with or containing copper chelating compounds |
| 06/29/2006 | WO2006068410A1 Novel 3-(2-amino-6-pyridinyl)-4-hydroxyphenyl amine derivatives |
| 06/29/2006 | WO2006068326A1 Novel polypeptide and the use thereof |
| 06/29/2006 | WO2006068266A1 PROSTAGLANDIN F2α DERIVATIVE CONTAINING PRODUCTS |
| 06/29/2006 | WO2006068254A1 Skin-whitening agent |
| 06/29/2006 | WO2006068232A1 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 06/29/2006 | WO2006068213A1 Glycine derivative and use thereof |
| 06/29/2006 | WO2006068212A1 Lipase inhibitor and preventive/remedy for skin diseases |
| 06/29/2006 | WO2006068208A1 Preventive or therapeutic agent for glaucoma |
| 06/29/2006 | WO2006068199A1 Metabolically stable 3-oxy-1,2,4-triazole derivatives |
| 06/29/2006 | WO2006068168A1 Biodegradable and bioresorbable material for medical use |
| 06/29/2006 | WO2006068166A1 Dry granulated substance and process for producing the same |
| 06/29/2006 | WO2006068164A1 Tricyclic compound and use thereof |
| 06/29/2006 | WO2006068163A1 Bicyclic pyrrole derivatives |
| 06/29/2006 | WO2006068162A1 Therapeutic agent for chronic obstructive pulmonary disease |
| 06/29/2006 | WO2006068133A1 Method of suppressing expression of nfat2 |
| 06/29/2006 | WO2006068117A1 Preventive for nephropathy and food having the function imparted thereto |
| 06/29/2006 | WO2006068105A1 Therapeutic agent for keratoconjunctive disorder |
| 06/29/2006 | WO2006068075A1 Peroxisome proliferator-activated recepotr ϝ ligand |
| 06/29/2006 | WO2006068058A1 Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine |
| 06/29/2006 | WO2006068041A1 Composition having effect of promoting the decomposition of body fat and food or food additive containing the same |
| 06/29/2006 | WO2006067985A1 Novel polyphenol glycoside derived from acerola |
| 06/29/2006 | WO2006067925A1 Hepatic function remedial agent |
| 06/29/2006 | WO2006067868A1 Arterial sclerosis preventive agent |
| 06/29/2006 | WO2006067866A1 Proanthocyanidin-containing composition |
| 06/29/2006 | WO2006067864A1 Proanthocyanidin-containing composition |
| 06/29/2006 | WO2006067862A1 Active substances k03-0132 and method of producing the same |
| 06/29/2006 | WO2006067823A2 Pharmaceutical composition comprising nifedipine and mesalazine for the treatment of rectoanal tenesmus |
| 06/29/2006 | WO2006067795A2 Novel polymorphic forms of atorvastatin lactone and process for preparing the same |
| 06/29/2006 | WO2006067614A2 Heteroaromatic derivatives useful as anticancer agents |
| 06/29/2006 | WO2006067611A1 Methods of modulating the activities of alpha7 nicotinic acetylcholine receptor |
| 06/29/2006 | WO2006067608A1 Aqueous formulations based on sodium hyaluronate for parenteral use |
| 06/29/2006 | WO2006067607A2 Polyacetylen compounds isolated from cussonia |
| 06/29/2006 | WO2006067606A1 Uridine derivatives as antiviral drugs against a flaviviridae, especially hcv |
| 06/29/2006 | WO2006067605A1 Stable pharmaceutical compositions of tiagabine and processes for their preparation |
| 06/29/2006 | WO2006067603A1 Therapeutic compounds isolated form calomeria amarnthoides |
| 06/29/2006 | WO2006067601A1 Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation |
| 06/29/2006 | WO2006067599A2 Stable oral benzimidazole compositions and process of preparation thereof |
| 06/29/2006 | WO2006067589A1 Macrolides |
| 06/29/2006 | WO2006067584A1 8-aza-bicyclo (3.2.1) octane derivatives with an activity on chemokine ccr5 receptors |
| 06/29/2006 | WO2006067532A1 G-protein coupled receptor agonists |
| 06/29/2006 | WO2006067531A1 G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| 06/29/2006 | WO2006067529A1 Piperidine and azetidine derivatives as glyt1 inhibitors |
| 06/29/2006 | WO2006067502A1 Treatment of inflammatory diseases |
| 06/29/2006 | WO2006067498A1 Eicosapentaenoic acid for the treatment of cancer |
| 06/29/2006 | WO2006067496A1 Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders |
| 06/29/2006 | WO2006067494A1 Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders |
| 06/29/2006 | WO2006067472A1 Parp inhibitors |
| 06/29/2006 | WO2006067446A1 Pyridine carboxamide derivatives for use as anticancer agents |
| 06/29/2006 | WO2006067444A1 Amide derivatives |
| 06/29/2006 | WO2006067443A1 Therapeutic agents |
| 06/29/2006 | WO2006067437A1 Oxygen containing heterocycles as glycine transporter inhibiting compounds |
| 06/29/2006 | WO2006067430A1 2-amino-1-phenylethylcarboxamide derivatives |
| 06/29/2006 | WO2006067428A2 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands |
| 06/29/2006 | WO2006067423A1 Glycine transport inhibitors |
| 06/29/2006 | WO2006067417A1 Glycine transport inhibitors |
| 06/29/2006 | WO2006067416A1 Chemical processes and intermediates |
| 06/29/2006 | WO2006067414A2 Glycine transport inhibitors |
| 06/29/2006 | WO2006067401A1 Heterocyclic compounds as ccr2b antagonists |
| 06/29/2006 | WO2006067392A2 Indole derivatives for the treatment of tuberculosis |
| 06/29/2006 | WO2006067391A1 Pyrazolylamino substituted quinazoles for the treatment of cancer |
| 06/29/2006 | WO2006067385A1 Chemical compounds |
| 06/29/2006 | WO2006067362A1 Treatment for severe melancholic depression with epa |
| 06/29/2006 | WO2006067330A1 Pharmaceutical compositions based on fluorinated sulphamides and sulphinimides |
| 06/29/2006 | WO2006067312A2 Painkilling association comprising a dihydroimidazopyrazine derivative |
| 06/29/2006 | WO2006067311A2 Cdc25 phosphatase inhibitors |
| 06/29/2006 | WO2006067310A2 Use of a dihydroim1dazopyrazine derivative for treating or preventing pain |
| 06/29/2006 | WO2006067175A1 Medicaments for the treatment or prevention of fibrotic diseases |
| 06/29/2006 | WO2006067168A1 Medicaments for the treatment or prevention of fibrotic diseases |
| 06/29/2006 | WO2006067150A1 Oral immediate release formulation of a poorly watersoluble active substance |
| 06/29/2006 | WO2006067141A1 Cladribine regimen for treating multiple sclerosis |
| 06/29/2006 | WO2006067139A1 Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists |
| 06/29/2006 | WO2006067134A1 Combination treatment for multiple sclerosis |
| 06/29/2006 | WO2006067114A1 Sulfonyl amino cyclic derivatives and use thereof |
| 06/29/2006 | WO2006067086A1 New 3-phenylpropionic acid derivatives for the treatment of diabetes |
| 06/29/2006 | WO2006067048A1 Quinoline derivatives for the treatment of latent tuberculosis |
| 06/29/2006 | WO2006066987A1 Anti-radical agents |
| 06/29/2006 | WO2006066978A1 Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics |
| 06/29/2006 | WO2006066968A1 Pyridine compounds for the treatment of prostaglandin mediated diseases |
| 06/29/2006 | WO2006066955A1 Quinoline derivative, use and production thereof, and drug containing the same |
| 06/29/2006 | WO2006066950A2 Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents |